Asif Ali is CFO at Protagonist Therapeutics, Inc (PTGX). They have made 9 open-market trades across 1 company since 2024, most recently 2026-09-30.
CIK 0001921163
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PTGX | 59,003 | $7.6M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PTGX | SELL · 10b5-1 | 2026-09-30 | 2026-10-02 | $141.78 | $8.3M | -2.9% | — | — |
| PTGX | SELL | 2026-04-20 | 2026-04-21 | $105.47 | $185K | -7.6% | -4.2% | +25.7% |
| PTGX | SELL | 2026-03-26 | 2026-03-27 | $104.24 | $2.6M | +5.1% | -0.5% | +23.8% |
| PTGX | SELL | 2026-01-27 | 2026-01-27 | $83.13 | $3.8M | +2.5% | +7.2% | +19.5% |
| PTGX | SELL | 2026-01-20 | 2026-01-21 | $82.48 | $708K | +0.3% | -0.1% | +27.8% |
| PTGX | SELL | 2025-04-22 | 2025-04-23 | $46.00 | $81K | -3.7% | -0.7% | +19.6% |
| PTGX | SELL | 2025-03-12 | 2025-03-14 | $58.73 | $2.9M | -8.5% | -16.9% | +4.0% |
| PTGX | SELL | 2024-09-11 | 2024-09-13 | $44.50 | $730K | -2.2% | -1.7% | -14.4% |
| PTGX | SELL | 2024-04-18 | 2024-04-19 | $25.11 | $31K | -1.1% | +21.0% | +38.2% |
| PTGX | SELL | 2024-02-29 | 2024-03-01 | $31.42 | $1.1M | -6.5% | -12.5% | -14.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.